Skip to main content

Table 2 Parkinson’s disease and control case information from substantia nigra received from PDUK Brain Bank

From: Reduced sphingolipid hydrolase activities, substrate accumulation and ganglioside decline in Parkinson’s disease

 Control subjectsPD subjects
Cohort size520
Female (%)2020
Male (%)8080
Age (years)83.4 ± 9.577.6 ± 6.9
PMI (hours)15.4 ± 6.915.9 ± 5.2
Disease duration (years)N/A13.5 ± 7.4
α-synuclein Braak scoreN/AScore 5: n = 5
Score 6: n = 15
Tau Braak scoreN/AScore 1 n = 8
Score 2: n = 11
Score 3: n = 1
  1. PMI post-mortem interval. Data summarised as mean ± SD. α-synuclein Braak score (ranging from 1 to 6) based on Alafuzoff et al., 2009, Acta Neuropathologica. Tau pathology Braak score (ranging from 1 to 6) based on Alafuzoff et al., 2008, Brain Pathology
  2. 3. Alafuzoff I, Ince PG, Arzberger T, Al-Sarraj S, Bell J, Bodi I, et al. Staging/typing of Lewy body related alpha-synuclein pathology: a study of the BrainNet Europe Consortium. Acta Neuropathol. 2009;117 (6):635–52
  3. 4. Alafuzoff I, Arzberger T, Al-Sarraj S, Bodi I, Bogdanovic N, Braak H, et al. Staging of neurofibrillary pathology in Alzheimer’s disease: a study of the BrainNet Europe Consortium. Brain Pathol. 2008;18 (4):484–96